Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease

Giovanni Musso,1 Roberto Gambino,2 and Maurizio Cassader2

1Gradenigo Hospital, Turin, Italy; email: giovanni_musso@yahoo.it
2Department of Internal Medicine, University of Turin, Italy

Key Words
NASH, farnesoid X receptor (FXR), pregnane X receptor (PXR), incretin, microRNA, AMP-activated kinase

Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic fat accumulation in the absence of significant ethanol consumption, viral infection, or other specific causes of liver disease. Currently the most common chronic liver disease, affecting 30% of the Western world, NAFLD may progress to cirrhosis and end-stage liver disease and may increase the risk of developing diabetes and cardiovascular disease. Although its pathogenesis is unclear, NAFLD is tightly associated with insulin resistance and the metabolic syndrome. No established treatment exists, and current research is targeting new molecular mechanisms that underlie NAFLD and associated cardiometabolic disorders. This review discusses some of these emerging molecular mechanisms and their therapeutic implications for the treatment of NAFLD: microRNAs, incretin analogs/antagonists, liver-specific thyromimetics, AMP-activated protein kinase activators, and nuclear receptors farnesoid X receptor and pregnane X receptor.
**INTRODUCTION**

Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic fat accumulation in the absence of significant ethanol consumption, viral infection, or other specific causes of liver disease. Currently the most common chronic liver disease in the world, NAFLD affects 30% of the Western adult population (1) and encompasses a spectrum of histological severity ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), the latter progressing to cirrhosis in 10%–25% of cases over 8–10 years (2). Although its pathogenesis is unclear, NAFLD is tightly associated with overall and central adiposity, insulin resistance, metabolic syndrome, and type 2 diabetes mellitus.

Currently there is no established treatment for NAFLD. Weight loss through lifestyle changes is difficult to achieve and maintain, and thiazolidinediones (a class of insulin sensitizers), a promising drugs for the treatment of NAFLD/NASH, pose weight-gain and long-term safety issues. Therefore, basic research is exploring new molecular mechanisms to target for the treatment of NAFLD and associated disorders.

**MICRORNAS AND NAFLD**

MicroRNAs (miRNAs) are a large class of genomically encoded 22-nucleotide-long RNAs that regulate target mRNAs in plants and animals through an antisense mechanism. Since the identification of the first miRNA, lin-4, in the nematode Caenorhabditis elegans (3), investigators have identified 695 miRNAs in humans, 488 in mouse, and 152 in the fly Drosophila melanogaster (4). It is increasingly understood that miRNA maturation is complex and highly modulated, subjecting these small posttranscriptional regulators of gene expression themselves to extensive posttranscriptional control. Each miRNA has several target genes, possibly dozens or hundreds, involved in diverse developmental and cellular processes, including cellular metabolism proliferation, differentiation, and apoptosis (5). Binding of the target gene results in modulation of the target mRNA through mechanisms that have not been fully elucidated but seem to involve translational repression, deadenylation and degradation of the target mRNAs (see sidebar MicroRNA Biogenesis and Regulatory Function). MicroRNA dysregulation has been implicated in various diseases, particularly cancers (6, 7). Accordingly, much effort has been put into developing profiling methods for miRNA expression patterns as experimental tools for the biologist and potential diagnostic and therapeutic tools for the clinician.

In liver diseases, most research on miRNAs focuses on their role in hepatocarcinogenesis. Microarray analysis and quantitative real-time polymerase chain reaction (RT-PCR) disclosed

---

**NAFLD**: nonalcoholic fatty liver disease  
**NASH**: nonalcoholic steatohepatitis
Table 1  Dysregulated miRNAs in liver diseases

<table>
<thead>
<tr>
<th>Disease</th>
<th>Dysregulated miRNA</th>
<th>Target gene/cellular function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocarcinoma</td>
<td>(+): 10b, 18, 20, 21, 221/222, 224</td>
<td>21: promotes cell invasion, migration, and growth via repression of the tumor suppressor PTEN</td>
</tr>
<tr>
<td></td>
<td>(−): 122, 145, 150, 199a, 199b, 200b, 214, 223</td>
<td>122: suppresses cyclin G1 expression; binds HCV-RNA enhancing its replication</td>
</tr>
<tr>
<td>Colangiocarcinoma</td>
<td>(+): 21, 23a, 27, 141, 200b</td>
<td>21: promotes gemcitabine resistance</td>
</tr>
<tr>
<td>NAFLD</td>
<td>(+): 10b, 15b, 21200b</td>
<td>10b: enhances peroxisome proliferator-activated receptor α expression</td>
</tr>
<tr>
<td></td>
<td>(−): 107/103, 122, 135a</td>
<td>15b: modulates insulin receptor, insulin-like growth factor 1 receptor, PGC-1α expression,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>lipopolysaccharide-induced TNF factor</td>
</tr>
</tbody>
</table>

Abbreviations/symbols: (−), downregulated; (+), upregulated; LDLRP-B, low-density lipoprotein receptor-related protein-B; PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1α; PTEN, phosphatase and tensin homolog.

aberrant miRNA expression profiles in primary hepatocarcinoma (HCC) compared with normal liver tissue (8, 9). MiRNA-21 promotes hepatocyte invasion, migration, and growth via repression of the tumor suppressor phosphatase and tensin homolog (PTEN), whose targeted deletion in murine hepatocytes leads to the development of HCCs (10), and the miRNAs 221–222 are associated with the outcome of HCCs. Among miRNAs downregulated in HCCs, miRNA-122 has received much attention because it is expressed specifically in the liver and accounts for 70% of the total liver miRNAs. Among the validated targets of miRNA-122, cyclin G1 and hepatitis C virus (HCV) have significance in HCCs. Indeed, cyclin G1 levels are increased in HCCs, and experimental models of hepatocarcinogenesis demonstrated that loss of cyclin G1 is associated with a significantly lower tumor incidence after carcinogen treatment, whereas HCV represents a predisposition factor for HCC. MiRNA-122 binds to the 5′ noncoding region of the HCV RNA genome, enhancing viral RNA replication (11). Consistently, miRNA-122 is downregulated in most of the mixed-etiology HCCs but upregulated in HCV-related HCCs, and interferon-β reduces hepatic miRNA-122 levels (12, 13).

The role of miRNAs in NAFLD is currently being investigated, as well. In human primary hepatocytes and in rats, the addition of monounsaturated olive oil upregulated the expression of miRNA-21, which bound to PTEN mRNA and induced its degradation. This in turn led to PTEN downregulation and hepatocyte fat infiltration (14). This study provides evidence for dietary regulation of miRNA-21 expression and may further link dietary fat excess to different liver disorders, given the emerging role of the tumor suppressor PTEN in the pathogenesis of NAFLD, NASH, and HCC (15).

Microarray and RT-PCR technology were utilized to detect dysregulated miRNAs in a rat model of NAFLD (16). Compared to healthy animals, there were 58 miRNAs upregulated and 51 miRNAs downregulated in NAFLD, most of which were differentially expressed in simple steatosis versus steatohepatitis. Putative target genes of dysregulated miRNAs were involved in hepatocyte proliferation, apoptosis, inflammation, and glucose and lipid metabolism (Table 1).
Finally, the hepatic expression profile of 474 miRNAs was assessed in patients with NASH. Compared with healthy controls, 23 miRNAs were differentially expressed in the liver of NASH subjects (17). Opposite to mouse models, hepatocyte miRNA-122 expression was 63% lower in human NASH; reduced miRNA-122 expression was associated with an increased expression of several target miRNA-122 lipogenic genes, including fatty acid synthase (FAS), 3-hydroxy-3-methyl-glutarylcoenzyme A reductase (HMG-CoA reductase), and their transcriptional activators, the sterol-response-element binding proteins 1c and 2 (SREBP-1c, SREBP-2). Intriguingly, in a subsequent experiment with cultured human hepatocytes, in vitro silencing and overexpression of miR-122 by reverse transfection were able to functionally modulate the expression of all these target genes and proteins involved in lipid synthesis.

The clinical implications of these data are twofold. First, the miRNA profile may serve as a diagnostic and prognostic biomarker in NAFLD, helping to noninvasively differentiate simple steatosis, which has a benign course, from progressive NASH, which can progress to cirrhosis and end-stage liver disease. Second, recent findings that antisense oligonucleotides can selectively block specific miRNAs in vitro and in vivo triggered efforts to explore miRNAs as a potential new class of therapeutics. A recent study demonstrated that intravenous injection of a short locked nucleic-acid-modified oligonucleotide (“LNA-antimir”) could block miR-122 activity in monkey, accompanied by a dose-dependent and long-lasting lowering of plasma cholesterol, without evidence of toxicity or carcinogenity (18). A phase I safety study in humans is ongoing. In high-fat-fed mice, silencing miR-122 by a 20-OMe phosphorothioate-modified antisense oligonucleotide specific to miR-122 (“antagomir”) resulted in a significant reduction of hepatic steatosis, which was associated with reduced cholesterol synthesis rates and stimulation of hepatic fatty acid oxidation (19, 20). Conversely, restoring miRNA function by the exogenous delivery of a synthetic miRNA mimic might have therapeutic benefit where tumor-suppressor miRNAs are underrepresented; a recent study demonstrated that viral delivery of let-7 inhibited tumor formation in mouse models of lung cancer (21).

These encouraging data suggest a miRNA-modulating strategy may prove an effective therapeutic approach for many metabolic and malignant diseases, including NASH. The upcoming challenges are (a) to identify all targets of deregulated miRNAs in these diseases and assess which miRNAs or antimicroRNAs can be used; (b) to ensure both the stability of the modulators in the body and, most importantly, delivery to, and uptake by, the organ or cells of interest; and (c) last, but not least, to assess carefully long-term safety of this approach.

INCRETIN ANALOGS/ANTAGONISTS

Incretin mimetics have received much attention in recent years because of their ability to stimulate pancreatic β-cell insulin secretion and growth, and they have been recently approved for the treatment of diabetes. Different strategies for enhancing incretin action have been proposed. These agents include glucagon-like peptide-1 (GLP-1) analogs, glucose-dependent insulinotropic polypeptide (GIP) agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the enzyme responsible for incretin inactivation.

It is increasingly recognized GLP-1 and GIP exert relevant extrahepatic actions that go well beyond their antidiabetic action (reviewed in 22) and may differentially affect their overall metabolic effects (Table 2).

The rationale for employing GLP-1 analogs in NAFLD lies in their weight-losing and intrahepatic effects (Table 2). Furthermore, reduced incretin action has been demonstrated in nondiabetic nonobese patients with NASH (23), thus prompting evaluation of GLP-1 analogs in fatty liver. In ob/ob mice, two months of exendin-4 induced a dose-dependent weight loss (7%–14% compared with placebo) and a significant improvement in hepatic steatosis,
Table 2  Similarities and differences between incretins GLP-1 and GIP

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>GLP-1</th>
<th>GIP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrine intestinal secreting cells</td>
<td>L-cells (distal ileum, colon)</td>
<td>K-cells (duodenum, jejunum)</td>
</tr>
<tr>
<td>Secretagogues</td>
<td>Glucose, leptin, fatty acids, essential</td>
<td>Glucose, fat (saturated &gt; unsaturated)</td>
</tr>
<tr>
<td></td>
<td>amino acids, vagal stimulation</td>
<td></td>
</tr>
<tr>
<td>Inhibitors of secretion</td>
<td>Insulin, somatostatin, galanin</td>
<td></td>
</tr>
<tr>
<td>Plasma half-life of bioactive</td>
<td>2 min</td>
<td>5–7 min</td>
</tr>
<tr>
<td>molecule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivating enzyme</td>
<td>Serine protease dipeptidyl peptidase-4 (DPP-4)</td>
<td>DPP-4</td>
</tr>
<tr>
<td>Molecular mediators of biological</td>
<td>AMP-activated PKA</td>
<td>cAMP-activated PKA</td>
</tr>
<tr>
<td>action in pancreas</td>
<td>PI-3K-activated PKC</td>
<td>PI-3K-activated PKC</td>
</tr>
<tr>
<td>Pancreatic actions</td>
<td>↓ K&lt;sub&gt;ATP&lt;/sub&gt; channels activity</td>
<td>↓ K&lt;sub&gt;ATP&lt;/sub&gt; channels activity</td>
</tr>
<tr>
<td></td>
<td>↑ Glucose-dependent insulin secretion</td>
<td>↑ Glucose-dependent insulin secretion</td>
</tr>
<tr>
<td></td>
<td>↑ β-cell proliferation</td>
<td>↑ β-cell proliferation</td>
</tr>
<tr>
<td></td>
<td>↓ β-cell apoptosis</td>
<td>↓ β-cell apoptosis</td>
</tr>
<tr>
<td></td>
<td>↑ Somatostatin secretion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>↓ Glucagon secretion</td>
<td></td>
</tr>
<tr>
<td>Central nervous system</td>
<td>↓ Appetite (hypothalamus)</td>
<td>GIP receptors expressed in hippocampus;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>unknown action</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td>↓ Gastric emptying and acid secretion</td>
<td>↓ Gastric acid secretion (supraphysiologic doses)</td>
</tr>
<tr>
<td>Net effect on body weight</td>
<td>↓</td>
<td>Neutral or slightly ↑</td>
</tr>
<tr>
<td>Circulating levels in diabetes</td>
<td>↓</td>
<td>Neutral or slightly ↑</td>
</tr>
<tr>
<td>Incretin effect in diabetes</td>
<td>Preserved</td>
<td>Blunted (receptor desensitization?)</td>
</tr>
<tr>
<td>Muscle</td>
<td>↑ Glucose uptake</td>
<td></td>
</tr>
<tr>
<td></td>
<td>↑ Glycogen synthesis</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>↑ Glycogen synthesis</td>
<td>↓ Glucagon-stimulated glucose production</td>
</tr>
<tr>
<td></td>
<td>↓ Gluconeogenesis</td>
<td>(indirect mechanisms: no GIP receptors in</td>
</tr>
<tr>
<td></td>
<td>↑ Intracellular cAMP levels</td>
<td>hepatocytes)</td>
</tr>
<tr>
<td>Adipose tissue</td>
<td>↑ Lipolysis</td>
<td>↑ Lipogenesis (↑ fatty acid synthesis, uptake and</td>
</tr>
<tr>
<td></td>
<td>↑ Glucose uptake</td>
<td>reesterification, ↑ LPL activity)</td>
</tr>
<tr>
<td></td>
<td>↑ Adiponectin secretion (94)</td>
<td>↓ Lipolysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>↑ Resistin/leptin secretion</td>
</tr>
<tr>
<td>Bone</td>
<td>?</td>
<td>↑ Osteoblast activity and bone remodeling</td>
</tr>
<tr>
<td>Kidney</td>
<td>↑ Natriuresis and diuresis</td>
<td>?</td>
</tr>
</tbody>
</table>

Abbreviations: cAMP, cyclic adenosine-monophosphate; PKA, protein kinase A; PKC, protein kinase C; LPL, lipoprotein lipase; PI-3K, phosphoinositide 3-kinase.

Insulin sensitivity, and plasma adipokine profile. These changes were associated with a marked increase in hepatocyte cAMP production and fatty acid oxidative pathways and with a decrease in hepatic lipogenesis and oxidative stress (24). In humans, Tushuizen et al. reported a 3.6-fold reduction in liver fat following 44 weeks of exenatide therapy in a diabetic man (25). In an open-label extension of three randomized placebo-controlled trials enrolling 217 overweight diabetic subjects, exenatide for three years was safe and well-tolerated, and it achieved a mean 5.3-kg weight loss as well as a significant reduction of serum transaminases, normalizing ALT levels in 41% of patients (26). Although these data suggest a possible role for GLP-1 agonists in the treatment of NAFLD, preclinical evidence suggests GIP may promote obesity-associated metabolic disorders (27). GIP operates as a key modulator
of lipid metabolism by stimulating glucose uptake, lipoprotein lipase activity, free fatty acid (FFA) synthesis, and incorporation in adipocytes (28). Furthermore, GIP administration stimulated resistin and leptin secretion in cultured adipocytes, an effect totally prevented by knocking out GIP receptor (29, 30). Consistent with these findings, acute and chronic administration of GIP, but not of GLP-1, induced fatty liver and other obesity-associated metabolic disorders in mice, whereas GIP antagonism reversed liver, muscle, and adipose tissue fat infiltration and ameliorated associated metabolic disturbances induced by high-fat diet in mice (31, 32).

Dietary fat is the most potent stimulator of GIP secretion. Saturated fat exerts higher stimulatory effects than unsaturated fat, and excessive saturated fat intake predisposes to diabetes, cardiovascular disease, and liver fat infiltration (33–37). Together these data suggest GIP may mediate the deleterious metabolic effects of a high-fat diet and may modulate adipocyte adipokine secretion, independently of its incretin effect on β-cell function (38).

Consistent with preclinical data, plasma GIP response to fat ingestion is exaggerated in non-diabetic nonobese patients with NASH and is associated with reduced β-cell function and incretin effect, as well as an unfavorable lipoprotein and adipokine profile (39). These findings suggest GIP may be an important mediator of the adipocyte response to nutritional excess, through molecular mechanisms still largely undefined, and may in part account for the increased metabolic risk of NAFLD.

The differential metabolic actions of GIP agonists, GLP-1 analogs, and DPP-4 inhibitors have been assessed in high-fat-fed mice, where the three classes of agents exerted different effects on β-cell function, insulin sensitivity, body weight, and adipokine levels. GLP-1 analog exendin-4 reduced food intake, and both exendin-4 and DPP-4 inhibitor prevented weight gain and ameliorated glucose tolerance and insulin sensitivity; GIP agonism did not prevent weight gain and was associated with worsened insulin sensitivity, increased circulating leptin and resistin, and a less pronounced improvement in glucose tolerance (40).

Therapeutically, as incretin analogs are evaluated in NAFLD, the relative merits of inhibition versus activation of GIP signaling should be considered. Specifically, while circulating levels of GLP-1 are reduced and pancreatic sensitivity to its incretin actions is preserved in obesity and diabetes, GIP has lost most of its insulin-stimulatory action, and its noxious extrapancreatic effects may offset the benefit of a blunted incretin effect. Although GLP-1-agonists may be potentially effective and harmless, the benefits of GIP antagonism may overcome ablation of the insulin-releasing GIP component of the entero-insular axis, which is already failing in obesity and diabetes; therefore a strategy with mixed GLP-1 agonism and GIP antagonism may be more effective for the treatment of NAFLD and obesity-related disorders (27).

**LIVER-SPECIFIC THYROMIMETICS**

The antiobesity and low-density lipoprotein (LDL)–cholesterol–lowering effects of thyroid hormones have been known for years, but their pharmacological use has been limited by their untoward effects on bone and heart and skeletal muscle. Recent research has developed drugs that lack these adverse effects and harness the beneficial effects of thyroid hormone. The development of these drugs, termed thyromimet-ics, was made possible by the existence of distinct thyroid hormone receptor (TR) subtypes with different tissue-specific distribution (41). There are two subtypes of TRs, TRα and TRβ, predominantly localized in the heart and liver, respectively. Splice variants of each gene generate different TR isoforms, four of which (TRα1, TRα2, TRβ1, and TRβ2) are expressed at the protein level in vivo (42).

Selective TRβ1 agonists have been synthesized and evaluated in preclinical trials and in a short clinical trial, showing their lipid-lowering properties and safety (43). The liver specificity
of these drugs is achieved through the selective hepatic distribution of phosphonic acid. A phosphonate-containing TRβ1 agonist is taken up predominantly by the liver with a high first-pass extraction and converted into the active form in hepatic microsomes by cytochrome P450 3A.

Recently, the main compound of this type, MB07811, has been evaluated in different animal models of hepatic steatosis, including ob/ob mice, Zucker diabetic rats, and mice with diet-induced obesity (44). At the end of treatment, liver triglyceride content was reduced by >66% in both normal and obese animals. A marked reduction was also observed in plasma cholesterol and triglyceride levels. Hepatic selectivity of MB07811 was demonstrated by showing that this agent did not affect circulating FFA levels, epididymal fat pad and heart mass, or pituitary thyroid-stimulating hormone mRNA. Intrahepatic mechanisms of action of MB07811 included an increased rate of mitochondrial β-oxidation, as assessed by (a) an increase in the mRNA levels of carnitine palmitoyltransferase-1 (CPT-1), a rate-limiting enzyme in the fatty acid oxidation cycle; (b) elevated levels of short and intermediate-length acyl-carnitine species in plasma; (c) increased mitochondrial respiration rates observed in ex vivo liver preparations; and (d) increased activity of hepatic mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH), an enzyme involved in energy production and dissipation. A decrease in hepatic lipogenesis, as suggested by a reduction in SREBP-1c mRNA, and in hepatic lipase activity, as suggested by reduced levels of apolipoprotein C3 (apoC3, an inhibitor of lipoprotein lipase), might also contribute to the antisteatotic effects of this agent.

Collectively, the results of these studies show promise for the treatment of NAFLD and associated metabolic disorders, but efficacy and safety of this class of agents in humans need further evaluation.

**AMP-ACTIVATED PROTEIN KINASE**

The discovery that many of the beneficial effects of metformin, physical exercise, caloric restriction, leptin, and adiponectin-mediated actions of thiazolidinediones converge on the enzyme AMP-activated protein kinase (AMPK) has renewed interest in the modulation of the activity of this kinase (see sidebar Structure and Molecular Activators of AMPK). Pharmacological AMPK activators are being developed for the treatment of multiple metabolic disorders, including NAFLD (47).

Regulation of AMPK activity involves both direct allosteric activation by AMP and reversible phosphorylation of AMPKα subunit on Thr172 by upstream kinases. The combination of the allosteric and phosphorylation effects amplifies kinase activity by >1000-fold, allowing a fine integrated sensing of cellular metabolism in response to small changes in energy status. Under conditions of high energy demand, intracellular ATP is reduced, AMP rises, and the AMP/ATP ratio provides a very
STRUCTURE AND MOLECULAR ACTIVATORS OF AMPK

AMPK is a heterotrimeric serine/threonine kinase composed of a catalytic α subunit and regulatory β and γ subunits. Multiple genes encode the three subunits (α1, α2, β1, β2, γ1, γ2, γ3), allowing 12 heterotrimeric combinations, with splice variants. Of the 12 theoretically possible complexes only 3 were detected in human skeletal muscle (α2β2γ1 ≫ α2β2γ3 = α1β2γ1). Serine/threonine kinase activity of AMPK is possessed by α subunits, which contain a threonine residue (Thr172) whose phosphorylation is required for AMPK activation. The β subunits contain a C-terminal region required for the association with α and γ subunits and a central region that allows AMPK complex to bind glycogen, which explains the tight regulation of glycogen metabolism by AMPK. The γ subunits contain four tandem repeats, known as the cystathionine β-synthase (CBS) motif, which bind two molecules of AMP or ATP in a mutually exclusive manner. Binding of AMP (on the γ subunit) activates AMPK allosterically and promotes phosphorylation of the α subunit (on Thr172) by upstream kinases as protein kinase LKB1 (calmodulin-dependent protein kinase kinase). Binding of AMP (on the γ subunit) inhibits Thr172 dephosphorylation by protein phosphatase, while binding of ATP strongly inhibits the activation of AMPK.

sensitive indication of cellular energy balance (48).

In the latest years, there has been increased interest in developing drugs that mimic the benefits of calorie restriction and physical exercise, which are the mainstay treatment for metabolic disorders but often cannot be achieved or maintained. Preclinical studies assessed the effects of pharmacological activation of AMPK on different organs and functions; the compound AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside), metabolized to ZMP, which is an analog of AMP, has been most extensively tested. In normal and insulin-resistant obese rats, infusion of AICAR suppressed hepatic glucose production, mostly through the phosphorylation and inactivation of a transcriptional coactivator, transducer of regulated CREB activity 2 (TORC2) (49, 50). TORC2 mediates CREB-dependent transcription of peroxisome-proliferator-activated receptor-γ coactivator 1α (PGC-1α) and its gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase).

Reduced hepatic glucose output was coupled with enhanced glucose disposal by skeletal muscle, which was mediated by increased translocation of glucose transporter GLUT4 to cell membranes, enhanced mitochondrial biogenesis, and enhanced glucose oxidation. These effects occur through a different mechanism than the insulin-signaling pathway, involving the phosphorylation of TBC1D1, a Rab-GTPase-activating protein that regulates the translocation of GLUT4 from intracellular vesicles to the plasma membrane by maintaining G-proteins named Rab in a GDP-bound state. The phosphorylation and subsequent inactivation of TBC1D1 allow the release and translocation of GLUT4 from the vesicle (51).

Besides glucose homeostasis, AMPK also regulates hepatic lipid metabolism. Its activation by AICAR, alpha-lipoic acid, or oltipraz has been shown to decrease liver fat content in lean and obese rodents (52–54). These effects were mediated by a direct phosphorylation and inactivation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) and acetyl-CoA carboxylase (ACC), key enzymes in hepatic cholesterol and fatty acid synthesis, and by inhibition of SREBP-1c-mediated transcription of key lipogenic enzymes, including fatty acid synthase, ACC, stearoyl-CoA desaturase-1, and ATP-binding cassette transporter A1 (55). Inhibition of ACC by AMPK leads to a fall in malonyl-CoA levels and subsequently removes the inhibition to mitochondrial fatty acid β-oxidation, eventually reducing excessive storage of triglycerides. Furthermore, AMPK activation directly leads to a significant activation of PGC-1α-mediated mitochondrial biogenesis, increasing mitochondrial number and enzymes in hepatocytes (56).

Other effects of AMPK activators include central appetite regulation, myocardial preconditioning and protection against ischemia and...
### Table 3 Activators, molecular mediators, and effects of AMP kinase in different tissues and organs

<table>
<thead>
<tr>
<th>Activators</th>
<th>Tissue</th>
<th>Molecular target</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical exercise</td>
<td>Skeletal muscle</td>
<td>↑ GLUT-4 translocation, ↑ Hexokinase II, ↑ PGC-1α-mediated mitochondrial biogenesis (97)</td>
<td>↑ Glucose uptake and oxidation, ↑ Insulin sensitivity</td>
</tr>
<tr>
<td>Starvation</td>
<td>Liver</td>
<td>↑ Phosphorylation of HMG-CoA reductase/PK/ACC, ↓ SREBP-1c-mediated lipogenesis, ↑ PGC-1α-mediated mitochondrial biogenesis</td>
<td>↓ Glucose production, ↓ Lipogenesis and cholesterol synthesis, ↑ Mitochondrial biogenesis and fatty acid β-oxidation</td>
</tr>
<tr>
<td>Biguanides, TZD (adiponectin-mediated)</td>
<td>Heart</td>
<td>↑ Glucose utilization, ↓ Myocyte hypertrophy</td>
<td>Protects myocytes against ischemia (ischemic preconditioning), ↓ Cardiac hypertrophy</td>
</tr>
<tr>
<td>Adiponectin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leptin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ghrelin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AICAR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thienopyridones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dithiolethiones (oltipraz)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alpha-lipoic acid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polyphenols (95, 96)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endothelium</td>
<td></td>
<td>↑ Endothelial NOS activity</td>
<td>↑ Endothelial function</td>
</tr>
<tr>
<td>Pancreatic β-cell</td>
<td></td>
<td>↑ Fatty acid and glucose oxidation, ↓ Insulin release by β-cell hyperpolarization</td>
<td>↓ Glucolipotoxicity, Spares β-cell function</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td></td>
<td>↑ Neuropeptide Y, ↑ Agouti-related peptide (AgRP), ↑ Mitochondrial fatty acid β-oxidation</td>
<td>↑ Appetite</td>
</tr>
</tbody>
</table>

Abbreviations: AICAR, 5-aminoimidazole-4-carboxamide ribonucleoside; SREBP-1c, sterol regulatory element binding protein-1c; PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1α; HMG-CoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A reductase; PK, pyruvate kinase; ACC, acetyl-CoA carboxylase.

hypertrophy (57–59), and endothelial function improvement through nitric-oxide-synthase-dependent and -independent mechanisms (60).

The benefits of AMPK activators on β-cell function are less well established (61, Table 3).

It is worth noting that the effects of AMPK activators are insulin independent and thus preserved in insulin-resistant-diabetic and obese subjects, such as those with NAFLD. These encouraging preclinical data need confirmation in human trials. The effects of AMPK activators on hepatic cellular mechanisms, other than lipogenesis, involved in necroinflammation and fibrogenesis are currently unknown, and such effects are crucial for the treatment of progressive NASH. In this context, AICAR infusion significantly reduced hepatic glucose output and whole-body lipolysis, decreasing blood glucose and FFA levels in a small group of diabetic subjects (62).

### NUCLEAR TRANSCRIPTION FACTORS: FARNESOID X RECEPTOR

Originally described as a farnesol-activated receptor, farnesoid X receptor (FXR) has been long known for its function of bile acid sensor in enterohepatic tissues (63). FXR has emerged in recent years as a master regulator of lipid and glucose homeostasis and of inflammatory processes at hepatic and extrahepatic sites, and a number of synthetic FXR agonists are being tested for the treatment of different hepatic and metabolic disorders (64, 65).

Two FXR genes have been identified, FXRa and FXRp. FXRa encodes four isoforms (FXRa1, FXRa2, FXRa3, and FXRa4) as a result of the use of alternative-RNA splicing.

FXRa is expressed mainly in the liver, intestine, kidney, and adrenal glands, and at much lower levels in adipose tissues. The second FXR
gene, FXRβ, is a lanosterol sensor that encodes a functional protein in rodents but not in humans.

FXR is an obligate partner of the 9-cis-retinoic acid receptor RXR (retinoic X receptor). The FXR/RXR heterodimer modulates gene expression through binding to specific DNA sequences called FXR response elements. Upon ligand binding, FXR undergoes conformational changes to release corepressors such as nuclear corepressor and recruit coactivators such as PGC-1α, CARM-1 (coactivator-associated arginine methyltransferase-1), DRIP-205 (vitamin-D-receptor-interacting protein-205), SRC-1 (steroid receptor coactivator-1), and PRMT-1 (protein arginine methyl transferase-1) (66). It is unclear how these coactivators are recruited by FXR ligands and how they are involved in specific gene regulation by FXR ligands.

The relevance of FXR to hepatic physiology and disease is known from the observation that FXR-deleted mice on a high-fat diet exhibit hyperlipidemia and massive hepatic steatosis, as well as necroinflammation and fibrogenesis (67, 68). Importantly, when mice knocked-out for LDL receptor (LDLR) and FXR were challenged with fat, high-fat led to knock-out for LDL receptor (LDLR) and FXR were challenged with fat, high-fat led to knock-out for LDL receptor (LDLR) and FXR were challenged with fat, high-fat led to necroinflammation and increased hepatic levels of tumor necrosis factor-α, intercellular adhesion molecule-1, transforming growth factor (TGF)-β, procollagen 1α1 and collagen, suggesting FXR may prevent progression of simple steatosis to NASH.

The molecular basis for these actions is being unraveled. FXR induces expression of genes that promote triglyceride clearance and mitochondrial fatty acid β-oxidation, together with a suppression of lipogenic gene transcription (69). Furthermore, small heterodimer partner (SHP), a nuclear receptor with corepressor activity that is strongly induced by FXR, interferes with SREBP-1c expression by inhibiting the activity of the liver X receptor, further reducing hepatic lipogenesis (70). FXR also upregulates the genes encoding apolipoprotein C-II (apoC-II) and very-low-density lipoprotein receptor, therefore enhancing triglyceride-rich lipoprotein clearance, while apoA-I gene expression is repressed (71). The latter action may explain the high-density-lipoprotein (HDL) cholesterol reduction observed in patients on bile acid supplementation, and the speculative increase in apoA-I and HDL cholesterol levels in subjects after ileal resection or on cholestyramine (72).

FXR regulates glucose homeostasis as well. In mice, FXR deletion promotes insulin resistance in both muscle and liver, leading to impaired glucose tolerance and hyperglycemia. Synthetic FXR agonists decrease glucagon in mice fed a high-fat diet by reducing the expression and activity of PEPCK, G6Pase, and fructose-1,6-bisphosphatase, and by enhancing insulin signaling through insulin-receptor substrate-1 (IRS-1) phosphorylation (73, 74).

In addition to its effects on glucose and lipid homeostasis, FXR appears to antagonize hepatic inflammatory and fibrogenetic processes. FXR agonists have been recently shown to antagonize nuclear factor (NF)-κB pathway activation in primary hepatocytes and in rodents challenged with bacterial lipopolysaccharide (LPS) (75). FXR−/− livers showed massive necroinflammation after treatment with LPS at a dose that did not induce significant liver damage in wild-type mice, whereas FXR activation suppressed NF-κB-mediated expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interferon-γ-inducible protein-10 (IP-10), and interferon-γ (IFN-γ) induced by LPS administration. Another hepatic protective mechanism of FXR activation against gut-derived endotoxins is represented by the maintenance of gut integrity through induction of antibacterial factors such as angiogenin, iNOS, and interleukin (IL)–18 (76). FXR also possesses anti-inflammatory properties. Synthetic FXR agonist 6-ethyl chenodeoxycholic acid (6-ECDCA) reduced the expression of the proinflammatory genes encoding collagen α1(I), α-smooth muscle
actin, tissue inhibitors of metalloproteinase 1 and 2, and TGF-β1 in cultured hepatic stellate cells. 6-ECDCA also reversed hepatic fibrosis in several rat models of liver injury (77, 78).

NUCLEAR TRANSCRIPTION FACTORS: PREGNANE X RECEPTOR

The pregnane X receptor (PXR) was initially identified as a nuclear receptor regulating xenobiotic and drug metabolism and elimination (79). Upon activation by a variety of ligands including drugs, insecticides, pesticides, and nutritional compounds, PXR forms a heterodimer with RXR that binds to PXR response elements, located in the 5′-flanking regions of target genes, resulting in their transcriptional activation. This “xenosensor” coordinates the expression of several genes encoding the most important xenobiotic metabolizing and transporting system, to inactivate and eliminate these compounds through four phases: uptake; oxidation (mostly through cytochrome P450 3A and 2B); conjugation by uridine-50-diphosphate glucuronosyltransferases (UGT), glutathione S-transferases (GST), or sulfono-transferases; and efflux, performed by transporters like multidrug resistance protein-1 (MDR1) (80).

It subsequently became clear that this system was also involved in catabolism of bile acid, bilirubin, and thyroid and steroid hormone, affecting their kinetics (81) (Tables 4 and 5).

Subsequent functional studies using PXR knockout and transgenic mice have implicated PXR in hepatic steatosis and carbohydrate and lipid homeostasis. Transgenic mice overexpressing the activated human PXR in the liver displayed marked hepatic triglyceride accumulation compared to the wild type (82). The lipogenic effect of PXR was independent of SREBP-1c and its primary target enzymes FAS and ACC-1. This effect occurred at 3 levels (83):

1. Enhanced de novo lipogenesis. PXR activation directly enhanced transcription of lipogenic enzymes stearoyl-CoA desaturase-1 (SCD-1) and fatty acid elongase (FAE). Furthermore, PXR enhanced transcription of lipogenic enzymes FAS and ATP citrate lyase (ACLY) by interacting with the thyroid-hormone-responsive SPOT14 homolog S14, a transcription regulator that is emerging as a key stimulator of lipogenesis induced by carbohydrate feeding and thyroid hormone administration (84).

2. Enhanced hepatocyte uptake of circulating FFA by the membrane fatty acid translocase fatty acid transporter (FAT)/CD36. Analysis of the mouse CD36 gene promoter revealed that CD36 is a direct transcriptional target of PXR. This regulation is achieved by binding of the PXR-RXR heterodimers to a PXR response element found in the CD36 gene promoter. Interestingly, the regulation of CD36 by PXR is liver specific. The same study found that activation of PXR also induced the expression of PPARγ, another positive regulator of CD36, suggesting that PXR can upregulate CD36 directly or indirectly through activation of PPARγ (82).

3. Downregulation of several genes involved in β-oxidation, including PPARα and thiolase (82–85). The notion that activation of PXR may suppress β-oxidation and influence lipogenesis was supported by a recent study by Nakamura et al. (86). These authors showed that treatment with PXR agonist pregnenolone-16α-carbonitrile (PCN) downregulated transcription of the genes encoding carnitine palmitoyltransferase 1a (CPT1a) and mitochondrial 3-hydroxy-3-methylglutarate-CoA synthase 2 (Hmgcs2) in the liver of fasting wild-type, but not PXR-null, mice (87). CPT1a is a key regulatory factor in insulin-dependent repression of β-oxidation, and Hmgcs2 is an enzyme important for ketogenesis. The SCD-1 mRNA was also found to be upregulated in PCN-treated wild-type mice, contributing to hepatic fatty infiltration. Consistent with the pattern of gene
### Table 4  Molecular mechanisms of action of farnesoid X receptor

<table>
<thead>
<tr>
<th>Activators</th>
<th>Molecular mechanisms</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bile acids (chenodeoxycholic acid)</td>
<td>↓ Expression of SREBP-1c and its lipogenic target genes (SHP-dependent and -independent mechanisms)</td>
<td>↓ Liver fat&lt;br&gt;↓ VLDL secretion and enhances its catabolism, thereby reducing plasma triglyceride levels&lt;br&gt;↓ Synthesis and uptake of HDL-C, with a net reduction in HDL-C levels</td>
</tr>
<tr>
<td>PUFA (arachidonic, linolenic, or docosahexanoic)</td>
<td>↑ Transcription of enzymes involved in fatty acid β-oxidation through PPAR-α activation&lt;br&gt;↓ ApoC-III and apoA-I synthesis&lt;br&gt;↑ ApoC-II synthesis and VLDL-receptor expression</td>
<td></td>
</tr>
<tr>
<td>Synthetic agonists (GW4064, 6-ECDCA, fexaramine)</td>
<td>↓ Hepatic expression of gluconeogenic enzymes PEPCK, G6-Pase and fructose-1,6-biphosphatase&lt;br&gt;↑ IRS-1 phosphorylation and coupling with the PI-3K activity</td>
<td>↓ Hepatic gluconeogenesis&lt;br&gt;↑ Hepatic insulin sensitivity</td>
</tr>
<tr>
<td>→ NF-κB-mediated activation of inflammation</td>
<td>↓ NF-κB-mediated expression of iNOS, COX-2, IP-10, and IFN-γ</td>
<td></td>
</tr>
<tr>
<td>→ Intestinal expression of antibacterial factors such as angiogenin, iNOS, and IL-18</td>
<td>Maintains gut integrity and impermeability to bacterial endotoxins</td>
<td></td>
</tr>
<tr>
<td>↓ Hepatic stellate cell expression of: collagen α(1), α-smooth muscle actin, tissue inhibitors of metalloproteinase 1 and 2, and TGF-β1 genes</td>
<td>↓ Hepatic fibrogenesis</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: PUFA, polyunsaturated fatty acid; 6-ECDCA, 6-ethyl chenodeoxycholic acid; SREBP-1c, sterol-response-element binding protein 1c; SHP, small heterodimer partner; VLDL, very-low-density lipoprotein; HDL, high-density lipoprotein; PPAR, peroxisome-proliferator-activated receptor; iNOS, inducible nitric oxide synthase; NF-κB, nuclear factor κB; TGF-β1, transforming growth factor β1; COX-2, cyclooxygenase-2; IP-10, interferon-γ-inducible protein 10; PEPCK, phosphoenol-pyruvate carboxykinase; IRS-1, insulin-receptor substrate-1; PI-3K, phosphoinositide 3-kinase.

### Table 5  Molecular mechanisms of action of pregnane X receptor

<table>
<thead>
<tr>
<th>Activators</th>
<th>Molecular mechanisms</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>5α-pregnenol-20,21-dione, progesterone, 17α-hydroxyprogesterone, 17α-hydroxypregnenolone and corticosterone, dexamethasone Antiglucocorticoids (pregnenolone-16α-carbonitrile, RU486) Tamoxifen Taxol Anti-infective chemotherapies (rifampicin, ritonavir, clotrimazole) Organochlorine pesticides</td>
<td>↑ Transcription of lipogenic enzymes SCD-1 and fatty acid elongase&lt;br&gt;↑ Transcription of lipogenic enzymes FAS and ATP citrate lyase (S14-mediated)&lt;br&gt;↑ Hepatocyte FFA uptake from plasma by FAT/CD36&lt;br&gt;↑ Carnitine palmitoyltransferase 1A (CPT1a), PPAR-α activation&lt;br&gt;↑ Glucogenesis&lt;br&gt;↓ Hepatic expression of PEPCK and G6-Pase (HNF-4/PGC-1α-mediated)&lt;br&gt;↓ Hepatic FOXO1 transcription</td>
<td>↑ De novo fatty acid synthesis and uptake from plasma&lt;br&gt;↓ Mitochondrial fatty acid oxidation&lt;br&gt;↓ Hepatic gluconeogenesis&lt;br&gt;↓ Hepatic fibrogenesis</td>
</tr>
</tbody>
</table>

Abbreviations: SCD-1, stearoyl-CoA desaturase-1; FFA, free fatty acid; FAS, fatty acid synthase; FAT, fatty acid transporter; HNF-4, hepatocyte nuclear factor-4; PGC-1α, PPARγ coactivator 1α; FOXO1, forkhead box-containing protein O subfamily-1.
respective regulation, the levels of hepatic triglycerides were increased and levels of serum 3-hydroxybutyrate were decreased in the PCN-treated wild-type mice. The same study showed that PXR could cross-talk with the insulin-responsive forkhead factor FoxA2 to suppress the transcription of the CPT1a and Hmgcs2 genes. The authors concluded that activation of PXR represses FoxA2-mediated transcription of CPT1a and Hmgcs2 genes in fasting liver.

PXR suppresses hepatic gluconeogenesis by competing with hepatocyte nuclear factor-4 (HNF-4) for the binding of PPARγ coactivator-1α (PGC-1α), thus attenuating HNF-4 signaling (88). The HNF-4/PGC-1α pathway plays a central role in regulating glucose/energy metabolism by regulating the gluconeogenic G6-Pase and PEPCK genes (89). PXR also acts as a corepressor of the transcription factor forkhead box-containing protein O subfamily-1 (FOXO1), another stimulator of gluconeogenesis. FOXO1 overexpression in NASH correlated with the severity of hepatic necroinflammation and insulin resistance (90, 91).

Besides regulating lipid metabolism, PXR has been proposed as a potential target for antifibrotic therapy. In a rat model of carbon tetrachloride-induced injury, hepatocyte necrosis and liver fibrosis were significantly inhibited by PXR agonists (92). These effects were replicated in cultured human primary hepatic stellate cells, where the PXR ligand rifampicin inhibited the expression of fibrogenic genes and reduced the proliferation and transdifferentiation to a profibrogenic phenotype of hepatic stellate cells. All of these effects were PXR dependent (93). The balance between the steatogenic and the antilipogenic and antifibrotic effects of PXR activation must be weighed in a clinical model before any conclusion can be drawn on the efficacy/safety profile of PXR antagonists as antifibrotic therapy.

**SUMMARY AND FUTURE DIRECTIONS**

With the growing epidemic of obesity, the prevalence of NAFLD will grow exponentially in the next 10 years. In the absence of an effective therapy, NASH is projected to be the leading cause of cirrhosis and liver transplantation by 2020. Ongoing research faces every aspect of the putative pathogenetic mechanisms of NAFLD, from insulin resistance to dysregulated hepatic lipid and glucose metabolism to increased hepatic inflammation and fibrogenesis. Ongoing research targets molecular mechanisms at the crossroads of multiple abnormalities accompanying NAFLD: hepatic glucose and triglyceride dysmetabolism, liver fat infiltration, inflammation, and fibrosis. As of May 2009, results of preclinical studies are encouraging. Two main challenges remain for the future: translating cellular/animal models to human pathology and testing the long-term safety and efficacy of those treatments that prove effective in preclinical trials.

**DISCLOSURE STATEMENT**

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

**ACKNOWLEDGMENTS**

This work was supported by grants from Piedmont Regional Research Project Funds CIPE 2008.
LITERATURE CITED


Contents

Using Genetic Diagnosis to Determine Individual Therapeutic Utility
C. Thomas Caskey ................................................................. 1

Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga
Tilo Grosser, Ying Yu, and Garret A. FitzGerald .................................... 17

Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Eugene O. Major ........................................................................... 35

The Future of Antiplatelet Therapy in Cardiovascular Disease
Carlo Patrono and Bianca Rocca ..................................................... 49

Pharmacogenetics of Warfarin
Farhad Kamali and Hilary Wynne ..................................................... 63

Heparin-Induced Thrombocytopenia
Gowthami M. Arepally and Thomas L. Ortel ....................................... 77

Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23
Clemens Bergwitz and Harald Jüppner .............................................. 91

Alveolar Surfactant Homeostasis and the Pathogenesis of Pulmonary Disease
Jeffrey A. Whitsett, Susan E. Wert, and Timothy E. Weaver .................. 105

Diagnosis and Treatment of Neuropsychiatric Disorders
Katherine H. Tabor, Robin A. Hurley, and Stuart C. Yudofsky ................. 121

Toward an Antibody-Based HIV-1 Vaccine
James A. Hoxie ........................................................................... 135

HIV-1 Vaccine Development After STEP
Dan H. Barouch and Bette Korber .................................................. 153

Growing Up with HIV: Children, Adolescents, and Young Adults with Perinatally Acquired HIV Infection
Rohan Hazra, George K. Siberry, and Lynne M. Mofenson ....................... 169
Genetic Aspects of Pancreatitis
David C. Whitcomb ................................................................. 413

Anorexia Nervosa: Current Status and Future Directions
Evelyn Attia ................................................................. 425

Structural Variation in the Human Genome and its Role in Disease
Pawel Stankiewicz and James R. Lupski ........................................ 437

Surgical Innovations Arising from the Iraq and Afghanistan Wars
Geoffrey S.F. Ling, Peter Rhee, and James M. Ecklund ......................... 457

Medicare Part D: Ongoing Challenges for Doctors and Patients
Gretchen Jacobson and Gerard Anderson ........................................ 469

Indexes

Cumulative Index of Contributing Authors, Volumes 57–61 ...................... 477
Cumulative Index of Chapter Titles, Volumes 57–61 ............................ 481

Errata

An online log of corrections to Annual Review of Medicine articles may be found at
http://med.annualreviews.org/errata.shtml